Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial

The health crisis caused by the new coronavirus SARS-CoV-2 highlights the need to identify new treatment strategies for this viral infection. During the past year, over 400 coronavirus disease (COVID-19) treatment patents have been registered; nevertheless, the presence of new virus variants has triggered more severe disease presentations and reduced treatment effectiveness, highlighting the need for new treatment options for the COVID-19. This study evaluates the Metformin Glycinate (MG) effect on the SARS-CoV-2 in vitro and in vivo viral load. The in vitro study was conducted in a model of Vero E6 cells, while the in vivo study was an adaptive, two-armed, randomized, prospective, longitudinal, double-blind, multicentric, and phase IIb clinical trial. Our in vitro results revealed that MG effectively inhibits viral replication after 48 h of exposure to the drug, with no cytotoxic effect in doses up to 100 µM. The effect of the MG was also tested against three variants of interest (alpha, delta, and epsilon), showing increased survival rates in cells treated with MG. These results are aligned with our clinical data, which indicates that MG treatment reduces SARS-CoV2-infected patients´ viral load in just 3.3 days and supplementary oxygen requirements compared with the control group. We expect our results can guide efforts to position MG as a therapeutic option for COVID-19 patients.

• Publication year

  2022

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2022-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2022.113223PMID 35709650PMCID 9159967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID‐19 patients with diabetes: A population‐based study in Lombardy

  2022cited by this paper
• Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing

  2021cited by this paper
• Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role

  2021cited by this paper
• Isolation and characterization of an early SARS-CoV-2 isolate from the 2020 epidemic in Medellín, Colombia

  2020cited by this paper
• Aislamiento y caracterización de una cepa temprana de SARS-CoV-2 durante la epidemia de 2020 en Medellín, Colombia

  2020cited by this paper
• Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment

  2020cited by this paper
• D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

  2020cited by this paper
• Hyperglycemia and COVID-19: What was known and what is really new?

  2020cited by this paper
• Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in Hepatitis C Virus RNA Replication Factories

  2020cited by this paper
• Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

  2020cited by this paper
• Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19

  2020cited by this paper
• Human Coronavirus: Host-Pathogen Interaction.

  2019cited by this paper
• Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice.

  2019cited by this paper
• Innate Immune Evasion by Human Respiratory RNA Viruses

  2019cited by this paper
• 146-LB: Efficacy and Safety of Metformin Glycinate vs. Metformin Hydrochloride in Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Mellitus Patients (T2DM)

  2019cited by this paper
• How Dengue Virus Circumvents Innate Immunity

  2018cited by this paper
• Lipid Tales of Viral Replication and Transmission.

  2017influential reference
• Ten Strategies of Interferon Evasion by Viruses

  2017cited by this paper
• Mechanisms of Cellular Membrane Reorganization to Support Hepatitis C Virus Replication

  2016cited by this paper
• Determination of 50% endpoint titer using a simple formula.

  2016cited by this paper
• Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.

  2015cited by this paper
• Membranous Replication Factories Induced by Plus-Strand RNA Viruses

  2014cited by this paper
• AMPK: a nutrient and energy sensor that maintains energy homeostasis

  2012cited by this paper
• Metformin interacts with AMPK through binding to γ subunit

  2012cited by this paper
• Protein Kinase D Negatively Regulates Hepatitis C Virus Secretion through Phosphorylation of Oxysterol-binding Protein and Ceramide Transfer Protein*

  2011cited by this paper
• Quantitative real-time PCR for rhinovirus, and its use in determining the relationship between TCID50 and the number of viral particles.

  2011cited by this paper
• Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells.

  2009cited by this paper
• FFAT rescues VAPA-mediated inhibition of ER-to-Golgi transport and VAPB-mediated ER aggregation

  2008cited by this paper
• Protein Phosphatase 2Cϵ Is an Endoplasmic Reticulum Integral Membrane Protein That Dephosphorylates the Ceramide Transport Protein CERT to Enhance Its Association with Organelle Membranes*

  2008cited by this paper
• Efficient Trafficking of Ceramide from the Endoplasmic Reticulum to the Golgi Apparatus Requires a VAMP-associated Protein-interacting FFAT Motif of CERT*

  2006cited by this paper
• Expression of Hepatitis C Virus Proteins Induces Distinct Membrane Alterations Including a Candidate Viral Replication Complex

  2002cited by this paper
• A Functional Role for VAP‐33 in Insulin‐Stimulated GLUT4 Traffic

  2000cited by this paper
• Goodpasture Antigen-binding Protein, the Kinase That Phosphorylates the Goodpasture Antigen, Is an Alternatively Spliced Variant Implicated in Autoimmune Pathogenesis*

  2000cited by this paper
• Comparison of MTT, XTT, and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays

  1992cited by this paper
• Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture.

  1991cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• Preventing Long COVID With Metformin.

  2026cites this paper
• A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID.

  2025cites this paper
• Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study.

  2025cites this paper
• Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial

  2025cites this paper
• Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.

  2025cites this paper
• Emerging uncertainty on the anti-aging potential of metformin.

  2025cites this paper
• Metformin as a Modulator of Mitochondria-Mediated Antiviral Innate Immunity: Insights from Molecular Docking Analysis

  2025cites this paper
• Metformin for covid-19: systematic review and meta-analysis of randomised controlled trials

  2025cites this paper
• Metformin alleviates inflammatory response and severity rate of COVID-19 infection in elderly individuals

  2025cites this paper
• Recent advances in nutritional metabolism studies on SARS-CoV-2 infection

  2025cites this paper
• Metformin inhibits the growth of SCLC cells by inducing autophagy and apoptosis via the suppression of EGFR and AKT signalling

  2025cites this paper
• Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes Mellitus on Anti-Hyperglycemic Medications

  2024cites this paper
• The interplay of aging, adipose tissue, and COVID-19: a potent alliance with implications for health

  2024cites this paper
• Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study

  2024cites this paper
• Metformin Alters mRNA Expression of FOXP3, RORC, and TBX21 and Modulates Gut Microbiota in COVID-19 Patients with Type 2 Diabetes

  2024cites this paper
• A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin

  2024cites this paper
• Cardiovascular disease as part of Long COVID: A systematic review.

  2024cites this paper
• Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

  2024cites this paper
• Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019.

  2024cites this paper
• The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus

  2024cites this paper
• Is there room for metformin at COVID-19's dinner table? Updated Analysis of Clinical Trials.

  2024cites this paper
• SARS-CoV-2 Spike Protein 1 Causes Aggregation of α-Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin

  2024cites this paper
• Metformin alleviates inflammatory response and severity rate of COVID-19 infection in elderly individuals

  2024cites this paper
• Long COVID as a Disease of Accelerated Biological Aging: An Opportunity to Translate Geroscience Interventions.

  2024cites this paper
• Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program.

  2024cites this paper
• Metformin – the old drug with new therapeutic possibilities

  2024cites this paper
• Metformin in Antiviral Therapy: Evidence and Perspectives

  2024cites this paper
• Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.

  2023cites this paper
• Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial

  2023cites this paper
• Nickel Photocatalyzed Reductive 1,4-Dicarbofunctionalization of 1,3-Enynes with N-Methylamines and Organohalides Enabled by Site-Selective C(sp3)-H Functionalization.

  2023cites this paper
• Metformin as a potential treatment for COVID-19

  2023cites this paper
• The power and pressure placed on clinicians and guideline panels.

  2023cites this paper
• Unveiling the potential pleiotropic effects of metformin in treating COVID-19: a comprehensive review

  2023cites this paper
• Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults

  2023cites this paper
• Optimization of Primary Human Bronchial Epithelial 3D Cell Culture with Donor-Matched Fibroblasts and Comparison of Two Different Culture Media

  2023cites this paper
• Repurposing exercise training and pharmacological therapies to address the post-acute sequelae of COVID-19 (PASC) in diabetes mellitus

  2023cites this paper
• Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges

  2023cites this paper
• Mechanisms and pathophysiology of SARS-CoV-2 infection of the adipose tissue.

  2023cites this paper
• Viral clearance in patients with COVID-19: associated factors and the role of antiviral treatment

  2023cites this paper
• Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2.

  2023cites this paper
• Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19

  2022cites this paper
• Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs

  2022cites this paper
• Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up

  2022cites this paper
• Insulin may increase disease severity and mortality of COVID-19 through Na+/H+ exchanger in patients with type 1 and type 2 diabetes mellitus

  2022cites this paper